drugset / Trial / NCT04250324
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma
Phase 1
Unknown
21 enrolled
Shanghai Cell Therapy Group Co.,Ltd
Institute of Hematology & Blood Diseases Hospital, China · collabTianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, dose-escalation phase 1 study to determine the Safety and Efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.
Timeline
- Start
- 2019-11-19
- Primary completion
- 2022-08
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BZ019 | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | BZ019 | Cell therapy | 6e+06 cells/kg | Intravenous |
| Subject | BZ019 | Cell therapy | 8e+06 cells/kg | Intravenous |
| Subject | BZ019 | Cell therapy | 1e+07 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |